# Ativa Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ativa-medical

- Industry: Medical Devices & Equipment
- Headquarters: St. Paul, US
- Website: www.ativamed.com
- Total disclosed funding: $15M
- Latest round: Series B (Aug 27, 2015)
- Investors on record: 5

## About

Ativa Medical focuses on developing innovative medical devices aimed at improving patient outcomes in respiratory care. Their solutions target critical health challenges, enhancing treatment efficiency and effectiveness.Founded in 2008 and headquartered in St. Paul, US, Ativa Medical specializes in respiratory care solutions. The company was raised through investment rounds including its most recent Series B round, where it secured USD 15.00 mn in August 2015 from investors such as Diamond BioFund and Laboratory Corporation of America Holdings. The founder, Barbara Roth, has a background in healthcare innovation, although there is no mention of previous companies she established.Ativa Medical specializes in developing advanced medical devices and solutions for respiratory care. Their offerings include devices that enhance patient monitoring and treatment delivery, specifically designed to meet the needs of healthcare providers and patients alike. These products are marketed globally, with significant uptake in North America, Europe, and parts of Asia, catering to various sectors including hospitals and outpatient facilities.Ativa Medical generates revenue primarily through the sale of medical devices and services associated with respiratory care. Their business model includes direct sales to healthcare institutions, emphasizing high-quality solutions that align with clinician needs. The pricing structure accommodates a range of clients, from small clinics to larger hospital systems, ensuring accessibility to their innovative products.Ativa Medical plans to leverage the recent USD 15.00 mn Series B financing to accelerate product development and expand its market reach. This includes the launch of new respiratory care devices, aimed for introduction in late 2016. The company is also targeting expansion into emerging markets in Asia by 2017, with a focus on increasing accessibility to their healthcare solutions.

## Funding rounds

- Series B, Aug 27, 2015, $15M — Laboratory Corporation of America Holdings, Ping An Trust, Hangzhou D.A. Diagnostics, Hermed Capital, Diamond BioFund

## Investors

- Laboratory Corporation of America Holdings — Series B
- Ping An Trust — Series B
- Hangzhou D.A. Diagnostics — Series B
- Hermed Capital (https://capitalatlas.ai/funds/hermed-capital) — Series B
- Diamond BioFund (https://capitalatlas.ai/funds/diamond-biofund) — Series B